IDYA is expected to report earnings to rise 4.83% to -62 cents per share on April 01
Q4'24
Est.
$-0.63
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.14
Q1'24
Missed
by $0.02
Q4'23
Missed
by $0.05
The last earnings report on November 04 showed earnings per share of -60 cents, beating the estimate of -62 cents. With 2.02M shares outstanding, the current market capitalization sits at 2.21B.
an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.